Adial Pharmaceuticals FY2025 net loss $8M, cash $5.9M; advancing AD04 toward Phase 3

ADIAL PHARMACEUTICALS, INC.

Net loss of $8.0M in FY2025 vs $13.2M in FY2024, driven by lower R&D and 2024 one-time $4.5M inducement expense.
Cash and cash equivalents $5.9M as of Dec 31, 2025, up from $3.8M; expected to fund operations into H2 2026.
Entered collaboration framework with Molteni for European AD04 commercialization; potential value ~$60M if successful.
Regained Nasdaq minimum bid price compliance on Feb 23, 2026; matter now closed.
Completed EOP2 meeting with FDA; secured U.S. manufacturing partners Cambrex and Thermo Fisher for late-stage development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADIAL PHARMACEUTICALS, INC. reported financial results for the 2025 fiscal year ended December 31, 2025.

Period: the 2025 fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 6, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”) issued a press release that included financial information for its fiscal year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-024336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.